I. COMMENCED TRADING IN JULY

INITIAL OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


There were no initial public offerings in July.

Total: $0M

Number of IPOs in July: 0

Average value of July IPOs: $0M

Number of IPOs for 2001: 8

Total raised in IPOs in 2001: $268.55M

Average value of IPOs in 2001: $33.57M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


Alteon Inc.
(AMEX:ALT)1

3/5

7/25

4.5S

$2.25

22.6

U.S. Bancorp Piper Jaffray

$10.13

$9.4

Charles River
Laboratories
International
Inc.
(NYSE:CRL)2

6/27

7/20

2S

$29

42.1

CS First Boston (co-lead); Lehman Brothers Inc. (co-lead); SG Cowen Securities Corp.; U.S. Bancorp Piper Jaffray

$58

$55.2

Inflazyme Pharmaceuticals Ltd. (Canada; TSE:IZP)3

6/19

7/9

3.75S

C$2.70 (US$1.76)

RBC Dominion Securities Inc.; CIBC World Markets Corp.; Yorkton Securities Inc.; Dlouhy Merchang Group Inc.

C$10.125 (US$6.59)

N/A

EXERCISED OVERALLOTMENT OPTIONS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


Arena
Pharmaceuticals
Inc. (ARNA)4

6/5

7/3

0.75S

$27.50

26.7

Thomas Weisel Partners LLC; Dain Rauscher Wessels; ABN Amro Rothschild LLC; Lazard Freres & Co. LLC

$20.6

$19.6

InterMune
Inc.
(ITMN)5

6/5

7/6

0.55S

$32

27.7

Lehman Brothers Inc.; Bank of America Securities Inc.; Robertson Stephens Inc.; UBS Warburg LLC

$37

N/A

Transkaryotic
Therapies Inc.
(TKTX)6

12/13

7/2

0.42S

$28.50

25.8

SG Cowen Securities Corp.

$12

N/A


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange

1. Alteon's offering includes an overallotment option for 300,000 shares.

2. Charles River's offering was for 8M shares, 6M of which were sold by selling stockholders. Underwriters have an overallotment option for 1.2M additional shares.

3. Inflazyme's underwriters have an overallotment option for 562,500 shares.

4. Arena completed a public offering in June, followed by the exercise of the overallotment option in July. The exercised option brought in another $20.6M making the total gross proceeds for $130.6M.

5. In June, InterMune raised $250M with the offering of shares and convertible subordinated notes. In July, it raised another $37M with the exercise of the overallotment option for 545,896 shares and $19.5M principal amount of the notes.

6. In June, Transkaryotic Therapies completed its offering. In July the overallotment option was exercised. The total offering involved 3.52M shares, which grossed $100.4M.

Total: $74.72M

Number of follow-on offerings in July: 3

Average value of July follow-ons: $24.9M

Number of follow-on offerings in 2001: 22

Total raised in follow-ons in 2001: $1,854.97M

Average value of follow-ons in 2001: $84.3M

II. FILED AND PENDING

INITIAL OFFERINGS

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


Acadia
Pharmaceuticals
Inc.
(ACAD)1

12/21

5S

$13-15

15.8

Robertson Stephens Inc. (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

APBiotech
(APBI; unit of
Nycomed
Amersham plc)2

10/3

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead); Goldman, Sachs & Co. (co-lead); Chase H&Q; Salomon Smith Barney

$291.2

BioNumerik
(BNPI)3

3/2

N/A

N/A

N/A

Morgan Stanley Dean Witter; UBS Warburg LLC; SG Cowen Securities Corp.

$50

CombiMatrix
Corp.
(CLMX)4

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead); J.P. Morgan & Co. (co-lead)

$100

diaDexus Inc.
(DDXS)5

11/20

7S

$12-14

31.1

Lehman Brothers Inc.; CIBC World Markets Corp.; Robertson Stephens Inc.; Fidelity Capital Markets

$91

NetGenics Inc.
(NTGC)6

3/13/00

5.5S

$11-13

23.5

Chase H&Q; UBS Warburg LLC

$66

Ribapharm
Inc.
(RIBA)7

5/15

18S

$13-15

N/A

UBS Warburg LLC; CIBC World Markets Corp.

$252

Senomyx Inc.

(SNMX)8

2/21

N/A

N/A

17.4

Deutsche Banc Alex. Brown; Bear, Stearns & Co. Inc.; CIBC World Markets Corp.

$80

Xcyte Therapies
Inc.
(XCYT)9

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead); U.S. Bancorp Piper Jaffray (co-lead); Dain Rauscher Inc.; First Security Van Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


Aastrom
Biosciences Inc.
(ASTM)10

12/7

7.7S

$0.96

33.84

N/A

$7.392

Alexion
Pharmaceuticals
Inc.
(ALXN)11

10/6

N/A

N/A

N/A

N/A

$300

Ariad
Pharmaceuticals
Inc.
(ARIA)12

6/22

4.5S

$4.79

34.6

N/A

$21.6

Atrix
Laboratories
Inc.
(ATRX)13

2/15

3S

N/A

18.2

Banc of America Securities (co-lead); U.S. Bancorp Piper Jaffray (co-lead); CIBC World Markets Corp.; Gruntal & Co. LLC

$100

Cell Pathways
Inc.
(CLPA)14

2/7

N/A

N/A

N/A

N/A

$25

Chiron Corp.
(CHIR)15

6/7

5.2S

$6.19

190

N/A

$400

ConjuChem
Inc.
(Canada;
TSE:CJC)16

5/30

N/A

N/A

N/A

Yorkton Securities; BMO Nesbitt Burns Inc.; HSBC Securities Inc.

N/A

Exelixis Inc.
(EXEL)17

7/30

N/A

N/A

48

N/A

$150

ICOS Corp.
(ICOS)18

6/26

N/A

N/A

53

N/A

$300

InSite Vision
Inc.
(AMEX:ISV)19

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co. (placement agent)

$40

Matrix
Pharmaceuticals
Inc.
(MATX)20

5/25

N/A

N/A

26

N/A

$30

Medarex Inc.
(MEDX)21

6/19

N/A

N/A

72.7

Goldman Sachs & Co.; Credit Suisse First Boston; JP Morgan; Morgan Stanley Dean Witter; Bear, Stearns & Co. Inc.; Dain Rauscher Wessels

$175

Microcide
Pharmaceuticals
Inc.
(MCDE)22

2/12

N/A

N/A

N/A

N/A

$35

NeoTherapeutics
Inc.
(NEOT)23

1/3

N/A

N/A

17.26

N/A

$50

Vion
Pharmaceuticals
Inc.
(VION)24

4/3

4.7S

$6.75

26.2

N/A

$31.73

ViroPharma
Inc.
(VPHM)25

7/3

N/A

N/A

18.7

N/A

$300

III. WITHDRAWN AND POSTPONED

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed/
Date
Pulled

Shares/
Units
(M)

Price
Range

Shares
Out (M)

Lead, Other Underwriters

Value
(M)


DNA Sciences
Inc.
(DNAS)26

1/5
7/20

N/A

N/A

N/A

Lehman Brothers Inc.; CIBC World Markets Corp.; Dain Rauscher Wessels Inc.

$125

Ethypharm
(France)27

6/18
7/2

10.94S

$8.95-
10.40

N/A

Schroder Salomon Smith Barney; ABN AMRO Rothschild; Robertson Stephens International; Banque Nomura France

EUR160
(US$137)

Meristem
Therapeutics
(France)28

6/27**
7/11**

2.275S

EUR22-
25.50
(US$18.90-
21.90)

N/A

Credit Lyonnais; WestLB Panmure

EUR54
(US$46)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

**Denotes the date the item ran in BioWorld International.

N/A = Not available or reported.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

1. Acadia's underwriters have an overallotment option for 750,000 shares.

2. APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

3. BioNumerik filed for a $50M IPO. The number of shares to be offered, the price range, and the number of shares outstanding were not disclosed.

4. CombiMatrix did not disclose any further details.

5. diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

6. NetGenics' IPO value, $66M, is based on the sale of 5.5M shares at $12 each, the midpoint of the expected price range. The underwriters have an overallotment option for 825,000 shares.

7. Ribapharm's IPO was originally proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

8. Senomyx did not disclose any further details.

9. Xcyte did not disclose any further details.

10. Aastrom amended its prospectus 12/29 increasing the offering from 6.35M shares to 7.7M shares. The offering value, $7.4M, is based on the proposed maximum aggregate price of $0.96 per share. The company placed 1.18M shares in a private placement in May, raising $1.1M. The company placed 1.89M shares in private placements in June, raising $2.95M. It also placed 1.05M shares in July, raising $1.5M.

11. Alexion filed a shelf registration to offer common stock, debt or warrants, up to a value of $300M.

12. Ariad's offering value is based on the proposed maximum offering share price of $4.79.

13. Atrix originally filed to offer 4M shares. It filed a preliminary prospectus supplement in July to offer 3M shares.

14. Cell Pathways filed a shelf registration for the sale of $25M in common stock.

15. Chiron Corp. plans to raise $400M through an offering of 30-year liquid yield option notes that could equate to 5.2M shares.

16. ConjuChem filed a preliminary prospectus for a new issue and secondary offering in Canada. No other information was made available.

17. Exelixis filed a shelf registration to sell up to $150M in common stock.

18. ICOS filed a shelf registration statement for up to $300M.

19. InSite filed a shelf registration to sell $40M in stock

20. Matrix filed a shelf registration covering up to $30M in securities.

21. Medarex plans to raise $175M through an offering of convertible notes due 2006. The offering will include an overallotment option for $26.25M principal amount of the notes to cover overallotments.

22. Microcide filed a shelf registration for the sale of up to $35M in securities.

23. NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. The company amended its prospectus April 19.

24. Vion filed a shelf registration statement to sell up to 5M shares, but later amended it to sell 4.7M shares. The value, $31.73M, is based on the 5/29 closing stock price of $6.75.

25. ViroPharma filed a universal shelf registration for $300M in mixed securities.

26. DNA Sciences withdrew its IPO, citing changes in its business and financing plans, recent market volatility and other considerations.

27. Ethypharm deferred its IPO on the Premier Marche exchange of Euronext Paris.

28. Meristem postponed its planned IPO on the Nouveau Marche of Euronext Paris due to market conditions.

No Comments